|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,329.50 GBX | -0.34% |
|
-1.08% | -8.32% |
| 05:18pm | GSK's Endometrial Cancer Drug Jemperli Secures EU Panel's Positive Opinion for Label Expansion | MT |
| 12-11 | GSK : Goldman Sachs reaffirms its Neutral rating | ZD |
| Capitalization | 54.43B 68.71B 65.46B 61.38B 97.82B 5,828B 108B 755B 279B 2,401B 258B 252B 10,558B | P/E ratio 2024 * |
14.8x | P/E ratio 2025 * | 9.47x |
|---|---|---|---|---|---|
| Enterprise value | 68.26B 86.16B 82.08B 76.96B 123B 7,308B 136B 946B 350B 3,011B 324B 316B 13,240B | EV / Sales 2024 * |
2.19x | EV / Sales 2025 * | 2.05x |
| Free-Float |
94.54% | Yield 2024 * |
4.52% | Yield 2025 * | 4.82% |
More valuation ratios
* Estimated data
More news
Last Transcript: GSK plc
More press releases
More news
| 1 day | -0.22% | ||
| 1 week | -1.08% | ||
| Current month | -0.41% | ||
| 1 month | -2.39% | ||
| 3 months | -18.61% | ||
| 6 months | -17.42% | ||
| Current year | -8.32% |
1 week
1 322.50
1 398.50
1 month
1 282.501 398.50
Current year
1 282.501 823.50
1 year
1 282.501 823.50
3 years
1 280.923 408.16
5 years
1 280.923 408.16
10 years
1 280.923 408.16
| Director | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 2017-03-31 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Manager | Title | Age | Since |
|---|---|---|---|
Emma Walmsley
BRD | Director/Board Member | 55 | 2016-12-31 |
Jesse Goodman
BRD | Director/Board Member | 72 | 2015-12-31 |
Hal Barron
BRD | Director/Board Member | 62 | 2017-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.17% | 11 M€ | +0.83% | - | |
| 3.15% | 20 M€ | +16.38% | - | |
| 2.97% | 55 M€ | +2.27% | - | |
| 2.51% | 8 M€ | +10.62% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -0.34% | -1.08% | -8.68% | -33.80% | 69.14B | ||
| +0.86% | -4.66% | +31.91% | +217.14% | 704B | ||
| -3.89% | -4.01% | +12.24% | +97.87% | 488B | ||
| -0.06% | -2.16% | -6.23% | -13.27% | 352B | ||
| +0.72% | -1.31% | +12.69% | +37.45% | 306B | ||
| +0.59% | -1.13% | -4.84% | +38.83% | 256B | ||
| -0.90% | -1.48% | +0.22% | -32.53% | 231B | ||
| -0.95% | -1.75% | +0.75% | +26.92% | 208B | ||
| -0.36% | -2.30% | +1.19% | +17.71% | 198B | ||
| -0.87% | -0.67% | -3.86% | +28.09% | 147B | ||
| Average | -0.52% | -1.52% | +3.54% | +38.44% | 296.09B | |
| Weighted average by Cap. | -0.54% | -1.91% | +9.52% | +74.61% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 31.16B 39.33B 37.47B 35.13B 55.99B 3,336B 61.89B 432B 160B 1,375B 148B 144B 6,044B | 32.27B 40.73B 38.81B 36.39B 57.99B 3,455B 64.1B 447B 165B 1,424B 153B 150B 6,259B |
| Net income | 3.67B 4.64B 4.42B 4.14B 6.6B 393B 7.29B 50.92B 18.83B 162B 17.42B 17.03B 712B | 5.78B 7.3B 6.95B 6.52B 10.39B 619B 11.48B 80.17B 29.65B 255B 27.42B 26.81B 1,122B |
| Net Debt | 13.82B 17.45B 16.62B 15.59B 24.84B 1,480B 27.46B 192B 70.89B 610B 65.56B 64.09B 2,681B | 11.69B 14.75B 14.06B 13.18B 21B 1,251B 23.22B 162B 59.94B 516B 55.44B 54.19B 2,267B |
More financial data
* Estimated data
Employees
70,212
Sector
Pharmaceuticals
Calendar
2024-12-17
- Analyst Meeting - Early Pipeline
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-12-13 | 1,329.50 p | -0.34% | 5,298,496 |
| 24-12-12 | 1,334.00 p | -0.48% | 6,664,431 |
| 24-12-11 | 1,340.50 p | -2.40% | 15,020,690 |
| 24-12-10 | 1,373.50 p | -0.69% | 6,016,717 |
| 24-12-09 | 1,383.00 p | +2.90% | 7,304,631 |
Delayed Quote London S.E., December 13, 2024 at 11:35 am
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
13.34GBP
Average target price
18.17GBP
Spread / Average Target
+36.20%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition